GINKGO BIOWORKS HOLDINGS, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
GINKGO BIOWORKS HOLDINGS, INC. (DNA) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-08-06
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-06-30 was $0.00.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $14.50M, a 35.32% increase year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $0.00.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $16.34M, a 21.52% decline from fiscal 2024.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $20.83M, a 52.71% decline from fiscal 2023.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $44.04M, a 327.19% increase from fiscal 2022.
- GINKGO BIOWORKS HOLDINGS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $10.31M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month as first filed | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $14.50M derived: sum of 3 quarters · filed 2026-08-06 | $14.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $14.50M derived: sum of 2 quarters · filed 2026-05-07 | $14.50M derived: sum of 3 quarters · filed 2026-05-07 | $14.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.50M derived: sum of 2 quarters · filed 2026-02-26 | $14.50M derived: sum of 3 quarters · filed 2026-08-06 | $16.34M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $1.84M 10-Q · filed 2025-11-06 | $12.56M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $1.84M 10-Q · filed 2026-08-06 | $12.56M derived: sum of 3 quarters · filed 2026-08-06 | $12.56M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.84M 10-Q · filed 2026-05-07 | $12.56M derived: sum of 2 quarters · filed 2026-05-07 | $12.56M derived: sum of 3 quarters · filed 2026-05-07 | $17.46M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.72M derived: sum of 2 quarters · filed 2026-02-26 | $15.62M derived: sum of 3 quarters · filed 2026-02-26 | $20.83M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $4.90M derived: sum of 2 quarters · filed 2025-11-06 | $10.11M 10-Q · filed 2025-11-06 | $19.34M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $4.90M 10-Q · filed 2025-08-07 | $10.11M 10-Q · filed 2025-08-07 | $19.34M derived: sum of 3 quarters · filed 2026-02-26 | $52.34M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $5.21M 10-Q · filed 2025-05-06 | $14.44M derived: sum of 2 quarters · filed 2026-02-26 | $47.44M derived: sum of 3 quarters · filed 2026-02-26 | $47.44M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.23M derived: sum of 2 quarters · filed 2026-02-26 | $42.23M derived: sum of 3 quarters · filed 2026-02-26 | $44.04M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $33.00M 10-Q · filed 2024-11-12 | $33.00M derived: sum of 2 quarters · filed 2024-11-12 | $34.81M 10-Q · filed 2024-11-12 | $1.80M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $1.81M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.81M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $10.31M 10-K · filed 2025-02-25 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |